Health Sciences Acquisitions Co. 2 (HSAQ) Competitors $3.16 -0.01 (-0.32%) As of 06/12/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsInsider TradesSEC FilingsTrendsBuy This Stock HSAQ vs. INFU, OBIO, ICAD, MBOT, GUTS, MGRM, SRTS, NSPR, INO, and CTCXShould you be buying Health Sciences Acquisitions Co. 2 stock or one of its competitors? The main competitors of Health Sciences Acquisitions Co. 2 include InfuSystem (INFU), Orchestra BioMed (OBIO), iCAD (ICAD), Microbot Medical (MBOT), Fractyl Health (GUTS), Monogram Orthopaedics (MGRM), Sensus Healthcare (SRTS), InspireMD (NSPR), Inovio Pharmaceuticals (INO), and Carmell (CTCX). These companies are all part of the "surgical & medical instruments" industry. Health Sciences Acquisitions Co. 2 vs. Its Competitors InfuSystem Orchestra BioMed iCAD Microbot Medical Fractyl Health Monogram Orthopaedics Sensus Healthcare InspireMD Inovio Pharmaceuticals Carmell InfuSystem (NYSE:INFU) and Health Sciences Acquisitions Co. 2 (NASDAQ:HSAQ) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, risk, media sentiment, analyst recommendations, valuation and community ranking. Which has stronger earnings & valuation, INFU or HSAQ? InfuSystem has higher revenue and earnings than Health Sciences Acquisitions Co. 2. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInfuSystem$137.58M0.95$870K$0.1444.29Health Sciences Acquisitions Co. 2N/AN/A-$380KN/AN/A Do analysts recommend INFU or HSAQ? InfuSystem presently has a consensus target price of $13.00, indicating a potential upside of 109.68%. Given InfuSystem's stronger consensus rating and higher possible upside, equities research analysts plainly believe InfuSystem is more favorable than Health Sciences Acquisitions Co. 2.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score InfuSystem 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 2 Strong Buy rating(s) 4.00Health Sciences Acquisitions Co. 2 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is INFU or HSAQ more profitable? InfuSystem has a net margin of 1.12% compared to Health Sciences Acquisitions Co. 2's net margin of 0.00%. InfuSystem's return on equity of 2.78% beat Health Sciences Acquisitions Co. 2's return on equity.Company Net Margins Return on Equity Return on Assets InfuSystem1.12% 2.78% 1.41% Health Sciences Acquisitions Co. 2 N/A N/A -2.38% Does the MarketBeat Community favor INFU or HSAQ? InfuSystem received 11 more outperform votes than Health Sciences Acquisitions Co. 2 when rated by MarketBeat users. CompanyUnderperformOutperformInfuSystemOutperform Votes11100.00% Underperform VotesNo VotesHealth Sciences Acquisitions Co. 2N/AN/A Do insiders & institutionals believe in INFU or HSAQ? 71.1% of InfuSystem shares are held by institutional investors. Comparatively, 89.7% of Health Sciences Acquisitions Co. 2 shares are held by institutional investors. 11.4% of InfuSystem shares are held by company insiders. Comparatively, 21.9% of Health Sciences Acquisitions Co. 2 shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Does the media refer more to INFU or HSAQ? In the previous week, InfuSystem had 2 more articles in the media than Health Sciences Acquisitions Co. 2. MarketBeat recorded 2 mentions for InfuSystem and 0 mentions for Health Sciences Acquisitions Co. 2. Health Sciences Acquisitions Co. 2's average media sentiment score of 0.00 beat InfuSystem's score of -1.00 indicating that Health Sciences Acquisitions Co. 2 is being referred to more favorably in the news media. Company Overall Sentiment InfuSystem Negative Health Sciences Acquisitions Co. 2 Neutral Which has more risk and volatility, INFU or HSAQ? InfuSystem has a beta of 1.81, suggesting that its share price is 81% more volatile than the S&P 500. Comparatively, Health Sciences Acquisitions Co. 2 has a beta of 0.09, suggesting that its share price is 91% less volatile than the S&P 500. SummaryInfuSystem beats Health Sciences Acquisitions Co. 2 on 11 of the 14 factors compared between the two stocks. Get Health Sciences Acquisitions Co. 2 News Delivered to You Automatically Sign up to receive the latest news and ratings for HSAQ and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding HSAQ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HSAQ vs. The Competition Export to ExcelMetricHealth Sciences Acquisitions Co. 2Surgical & medical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$35.43M$4.33B$5.59B$8.51BDividend YieldN/A42.67%5.28%4.17%P/E RatioN/A27.9127.2019.68Price / SalesN/A68.81409.08153.66Price / CashN/A51.0838.3234.64Price / Book-5.105.756.974.61Net Income-$380K$66.95M$3.23B$248.06M7 Day Performance3.61%-2.47%-0.72%-0.82%1 Month Performance19.25%15.14%8.00%3.74%1 Year Performance-59.59%18.18%31.77%13.02% Health Sciences Acquisitions Co. 2 Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HSAQHealth Sciences Acquisitions Co. 2N/A$3.16-0.3%N/A-57.9%$35.43MN/A0.004INFUInfuSystem2.397 of 5 stars$6.02+6.0%$13.00+115.9%N/A$126.52M$137.58M100.35410News CoverageNegative NewsShort Interest ↑OBIOOrchestra BioMed3.0771 of 5 stars$3.10-1.9%$14.20+358.1%-60.2%$118.77M$2.89M-1.934Positive NewsICADiCAD1.0414 of 5 stars$3.92+1.0%N/A+144.2%$107.69M$19.53M-30.15140News CoverageShort Interest ↓MBOTMicrobot Medical1.9545 of 5 stars$2.68+0.4%$9.00+235.8%+127.5%$97.49MN/A-3.3520News CoverageAnalyst RevisionGUTSFractyl Health2.4043 of 5 stars$1.89-0.5%$11.00+482.0%-64.4%$92.57M$60K-0.16102News CoverageMGRMMonogram Orthopaedics2.9328 of 5 stars$2.44+1.2%$5.40+121.3%+24.6%$87.08M$365.00K-5.1928Positive NewsSRTSSensus Healthcare2.5022 of 5 stars$4.81+1.9%$11.67+142.6%-8.8%$79.10M$39.49M12.0340Positive NewsNSPRInspireMD2.0373 of 5 stars$2.55+0.4%$4.50+76.5%-4.9%$78.12M$7.03M-3.4050News CoverageINOInovio Pharmaceuticals4.0638 of 5 stars$2.12+1.0%$9.75+359.9%-78.1%$77.75M$283.10K-0.66320Positive NewsCTCXCarmellN/A$3.27-0.9%N/A+26.8%$68.36M$32.84K0.0014News Coverage Related Companies and Tools Related Companies InfuSystem Competitors Orchestra BioMed Competitors iCAD Competitors Microbot Medical Competitors Fractyl Health Competitors Monogram Orthopaedics Competitors Sensus Healthcare Competitors InspireMD Competitors Inovio Pharmaceuticals Competitors Carmell Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:HSAQ) was last updated on 6/13/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredBanks aren’t ready for this altcoin—are you?Donald Trump just fast-tracked TWO major crypto bills with an August deadline! Your window of opportunity i...Crypto 101 Media | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Health Sciences Acquisitions Co. 2 Please log in to your account or sign up in order to add this asset to your watchlist. Share Health Sciences Acquisitions Co. 2 With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
